0.00Open0.00Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover852.84%IV-77.53%PremiumAug 16, 2024Expiry Date1.73Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9589Delta0.0210Gamma1.16Leverage Ratio-0.0107Theta0.0001Rho1.11Eff Leverage0.0004Vega
Standard BioTools Stock Discussion
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Benzinga· 1 min ago
No comment yet